A new ALK inhibitor overcomes resistance to first- and second-generation inhibitors in NSCLC.
Lu Y, Fan Z, Zhu SJ, Huang X, Zhuang Z, Li Y, Deng Z, Gao L, Hong X, Zhang T, Li L, Sun X, Huang W, Zhang J, Liu Y, Zhang B, Jiang J, Gui F, Wang Z, Li Q, Song S, Huang X, Wu Q, Chen L, Zhou D, Zhang J, Yun CH, Chen L, Deng X.
Lu Y, et al. Among authors: zhang b, zhang t, zhang j.
EMBO Mol Med. 2022 Jan 11;14(1):e14296. doi: 10.15252/emmm.202114296. Epub 2021 Nov 30.
EMBO Mol Med. 2022.
PMID: 34845836
Free PMC article.